Plus   Neg

Mark Your Calendar: These 4 Pharma Stocks Are Prepping For The Big Day

meeting jun24 lt

Clinical trial results announcements are make or break events for biotech/pharma companies, and more so -- if they are small or mid-cap companies.

The phase III trials, which are the longest and most expensive trials to conduct, are said to have a success rate of 58%, according to a report from the Biotechnology Innovation Organization on "Clinical Development Success Rates" over the past decade (2006-2015).

The following are some of the companies that are slated to report phase III trial results in the coming weeks. Do you have these stocks in your portfolio?

1. Akcea Therapeutics

Akcea Therapeutics Inc. (AKCA), an affiliate of Ionis Pharmaceuticals (IONS), is a
commercial-stage company focused on developing RNA-targeted antisense therapeutics to treat patients with serious cardiometabolic diseases caused by lipid disorders.

Watch out for...

The top-line results from phase III study of Waylivra (volanesorsen) for the
treatment of familial partial lipodystrophy are due in the middle of this year.
Familial partial lipodystrophy is a rare condition characterized by an abnormal
distribution of fatty (adipose) tissue. (Source: NIH).

Waylivra received conditional marketing authorization from the European Commission in May of this year as an adjunct to diet in adult patients with genetically confirmed familial chylomicronaemia syndrome and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate.

Familial chylomicronaemia syndrome is a rare genetic disorder that causes build-up of chylomicrons in the blood that can lead to abdominal pain and potentially fatal bouts of pancreatitis. Chylomicrons are the largest lipoprotein particle, which are responsible for transporting dietary fat and cholesterol. (Source: RAREDR).

AKCA closed Friday's trading at $24.26, up 5.94%.

2. Deciphera Pharmaceuticals

Deciphera Pharmaceuticals Inc. (DCPH) is a clinical-stage biopharmaceutical company
focused on addressing key mechanisms of tumor drug resistance.

The Company's lead drug candidate is Ripretinib, an orally administered kinase switch control inhibitor being developed for the treatment of gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors.

Watch out for...

The top-line data from a phase III clinical study of Ripretinib in fourth-line and fourth-line plus gastrointestinal stromal tumor patients are due in mid-2019.

Gastrointestinal stromal tumors are uncommon tumors of the gastrointestinal (GI) tract. These tumors start in very early forms of special cells in the wall of the GI tract called the interstitial cells of Cajal (ICCs). (Source: American Cancer Society).

DCPH closed Friday's trading at $26.21, up 4.84%.

3. Intra-Cellular Therapies Inc. (ITCI)

Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease.

The Company's lead drug candidate is Lumateperone, which is under phase III clinical development for the treatment of schizophrenia, bipolar depression and agitation associated with dementia, including Alzheimer's disease.

Watch out for...

Topline results from two phase III trials of Lumateperone as monotherapy in bipolar depression, dubbed Study 401 and Study 404, are due this quarter.

ITCI closed Friday's trading at $13.28, up 2.95%.

4. Sol-Gel Technologies

Sol-Gel Technologies Ltd. (SLGL) is a clinical-stage dermatology company.

The Company's lead drug candidate is EPSOLAY, an innovative topical encapsulated benzoyl peroxide cream with a 5% concentration for the treatment of papulopustular rosacea.

Papulopustular rosacea is a subtype of rosacea, a chronic inflammatory skin condition. It is characterized by persistent redness with transient papules and pastules (bumps and pimples). (Source: NCBI)

EPSOLAY is under a pivotal Phase III clinical program, consisting of two randomized, multi-center, double-blind, vehicle-controlled clinical trials at 50 sites in the United States.

Watch out for...

Top-line results from the pivotal Phase III Epsolay trials in papulopustular rosacea are due in mid-2019.

SLGL closed Friday's trading at $9.25, up 1.48%.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT